Maxi Wass, Stefanie Göllner, Birgit Besenbeck, Richard F Schlenk, Petra Mundmann, Joachim R Göthert, Richard Noppeney, Christoph Schliemann, Jan-Henrik Mikesch, Georg Lenz, Martin Dugas, Martin Wermke, Christoph Röllig, Martin Bornhäuser, Hubert Serve, Uwe Platzbecker, Kathrin I Foerster, Jürgen Burhenne, Walter E Haefeli, Lutz P Müller, Mascha Binder, Caroline Pabst, Carsten Müller-Tidow
All-trans-retinoic acid (ATRA) is highly active in acute promyelocytic leukemia but not in other types of acute myeloid leukemia (AML). Previously, we showed that ATRA in combination with Lysine-specific demethylase 1 (LSD1) inhibition by tranylcypromine (TCP) can induce myeloid differentiation in AML blasts. This phase I/II clinical trial investigated the safety and efficacy of TCP/ATRA treatment as salvage therapy for relapsed/refractory (r/r) AML. The combination was evaluated in 18 patients, ineligible for intensive treatment...
March 2021: Leukemia